1093341-40-2 Usage
Molecular Structure
2,2-difluoro-2-(quinolin-6-yl)acetic acid consists of a quinoline ring and a difluoroacetic acid group.
Functional Groups
The compound contains a heterocyclic aromatic quinoline ring and a difluoroacetic acid group.
Biological Activity
The quinoline ring in the compound has various biological activities.
Unique Properties
The difluoroacetic acid group adds unique properties to the molecule.
Applications
The compound has potential applications in the development of pharmaceutical drugs, particularly in the treatment of diseases such as cancer and infectious diseases.
Value in Synthesis
2,2-difluoro-2-(quinolin-6-yl)acetic acid is a valuable building block for synthesizing novel compounds with therapeutic potential.
Check Digit Verification of cas no
The CAS Registry Mumber 1093341-40-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,3,3,4 and 1 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1093341-40:
(9*1)+(8*0)+(7*9)+(6*3)+(5*3)+(4*4)+(3*1)+(2*4)+(1*0)=132
132 % 10 = 2
So 1093341-40-2 is a valid CAS Registry Number.
1093341-40-2Relevant academic research and scientific papers
Discovery of potent and selective 8-fluorotriazolopyridine c-met inhibitors
Peterson, Emily A.,Teffera, Yohannes,Albrecht, Brian K.,Bauer, David,Bellon, Steven F.,Boezio, Alessandro,Boezio, Christiane,Broome, Martin A.,Choquette, Deborah,Copeland, Katrina W.,Dussault, Isabelle,Lewis, Richard,Lin, Min-Hwa Jasmine,Lohman, Julia,Liu, Jingzhou,Potashman, Michele,Rex, Karen,Shimanovich, Roman,Whittington, Douglas A.,Vaida, Karina R.,Harmange, Jean-Christophe
, p. 2417 - 2430 (2015/03/30)
The overexpression of c-Met and/or hepatocyte growth factor (HGF), the amplification of the MET gene, and mutations in the c-Met kinase domain can activate signaling pathways that contribute to cancer progression by enabling tumor cell proliferation, survival, invasion, and metastasis. Herein, we report the discovery of 8-fluorotriazolopyridines as inhibitors of c-Met activity. Optimization of the 8-fluorotriazolopyridine scaffold through the combination of structure-based drug design, SAR studies, and metabolite identification provided potent (cellular IC50 a mouse liver pharmacodynamic model.
